---
title: "Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295829552.md"
description: "Royalty Pharma agreed to a $100 million funding pact with Zealand Pharma for economic rights to the blood disorder drug rusfertide. The deal includes a 1% royalty on global net sales and milestone payments, with half paid at closing and half on the first anniversary. Takeda holds global commercialization rights, and FDA action is expected in Q3 2026."
datetime: "2026-08-13T17:07:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295829552.md)
  - [en](https://longbridge.com/en/news/295829552.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295829552.md)
generator: "portal-rs"
---

# Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug

**Royalty Pharma plc** (NASDAQ:RPRX) on Wednesday entered into a $100 million funding agreement with **Zealand Pharma** in exchange for economic rights related to Zealand’s product, Rusfertide (PTG-300).

This strategic move is expected to bolster Royalty Pharma’s portfolio and enhance its revenue streams.

The U.S. FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application for rusfertide for polycythemia vera in the third quarter of 2026.

**Takeda Pharmaceutical Co Ltd** (NYSE:TAK) will be responsible for global commercialization.

Royalty Pharma will pay Zealand Pharma $100 million for economic interests tied to rusfertide, including a 1% royalty on potential future global net sales and regulatory and commercial milestones.

Zealand Pharma will receive $50 million at closing and another $50 million on the first anniversary of the agreement. 

The company will retain a 0.25% royalty on annual global net sales above $1.5 billion, while Royalty Pharma will receive a 0.75% royalty on sales exceeding that threshold.

 **Read Also: Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'** 

## Prior Rusfertide Collaboration

Zealand Pharma and **Protagonist Therapeutics Inc.** (NASDAQ:PTGX) entered a research collaboration in June 2012 to develop disulfide-rich peptides.

Zealand Pharma handled preclinical and clinical development of compounds discovered through the collaboration.

The collaboration ended in 2014, with Protagonist’s payment obligations to Zealand Pharma clarified under a 2021 settlement agreement.

In January 2024, Protagonist and Takeda entered into a worldwide license and collaboration agreement for rusfertide.

In July, Royalty Pharma acquired a portion of Neurimmune’s royalty interest in **AstraZeneca plc’s** (NYSE:AZN) cliramitug for up to $425 million.

Cliramitug is a Phase 3 TTR-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy.

Cliramitug is currently in the Phase 3 DepleTTR-CM trial with results expected in 2028.

## RPRX Technical Outlook: Trend Vs Key Moving Averages

-   The stock is currently trading at $59.37, which is 1.3% above its 20-day simple moving average (SMA) of $58.32 and 4.1% above its 50-day SMA of $56.76.
-   The moving average convergence divergence (MACD) is below its signal line.

**RPRX Stock Price Activity:** Royalty Pharma shares were up 0.25% at $59.37 at the time of publication on Thursday, according to Benzinga Pro data.

 **Read Also: Cisco Says It's Taking Customers From Rivals. Is Arista's Lead Narrowing?** 

*Photo by Piotr Swat via Shutterstock*

### Related Stocks

- [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md)
- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)
- [PTGX.US](https://longbridge.com/en/quote/PTGX.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [CSCO.US](https://longbridge.com/en/quote/CSCO.US.md)
- [ANET.US](https://longbridge.com/en/quote/ANET.US.md)

## Related News & Research

- [Royalty Pharma (RPRX) Following Mixed Earnings Still Looks Close To Fair Value](https://longbridge.com/en/news/295686556.md)
- [Royalty Pharma EVP and Chairman of Partnering Christopher Hite sells 100,000 shares for $6 million](https://longbridge.com/en/news/296396564.md)
- [CMI adopts orphan drug field with dedicated center of excellence](https://longbridge.com/en/news/296242891.md)
- [Royalty Pharma CFO Terrance P. Coyne sells USD 645,248 in common shares](https://longbridge.com/en/news/296146007.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**